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LETTER TO THE EDITOR
Dear Sir,
We were interested to read the paper by Price
et al. (2004;98:17–24) which purported to show an
association between antibiotic prescribing trends in
general practice and community-acquired pneumo-
nia mortality. We are concerned that there are
serious methodological flaws in this paper which we
would like to bring to your attention.
The endpoint used was imprecise and potentially
inaccurate. The title of the paper refers to
community-acquired pneumonia mortality. The
source for this was death certificate data for
England and Wales with pneumonia as the cause
of death, excluding cases where this was a
consequence of underlying disease. As the authors
acknowledge, diagnosis of pneumonia outside
hospital is difficult both in life and at death. Death
certificate data will include not only community-
acquired pneumonia, but also an unknown number
of cases of hospital-acquired pneumonia, aspiration
pneumonia and pneumonias in the immunocompro-
mised and also other non-pneumonia respiratory
conditions where general practitioner (GP) anti-
biotic prescribing is unlikely to have influenced
outcome. In a study using death certificate data,
with pneumonia as the ‘Underlying Cause of Death’
where the additional step of contacting the doctor
responsible for care of the individual’s final illness
was taken, additional information was identified,
not provided on the death certificate, that may
have been relevant to the death, in 72% of cases.1
In a separate study, national death certificate data
from Scotland were found to overestimate true
community-acquired pneumonia mortality by a
factor of two, largely due to the use of the poorly
defined label of ‘bronchopneumonia’ which was
also included in the ICD9 pneumonia codes used by
Price et al.2
Antibiotic prescribing data were obtained from a
different population, a UK (not England and Wales)
database for seventeen ICD10 (not Read as stated in
the paper) codes that might be considered to
reflect lower respiratory tract infection (LRTI).
Only five of these were for pneumonia, with the
majority likely to represent the condition that GPs
label as acute bronchitis. Data were not age
corrected. Of the 439 948 pneumonia deaths
between January 1993 and December 2000, 95%
were in the 464 years age group. This is the age
group in which the smallest (maximum 5.9%)
reduction in GP antibiotic prescribing has occurred
(compared to a maximum of 26.1% in the o16
years age group).3 Any association between anti-
biotic prescribing and pneumonia mortality must be
based on prescribing in this older age group. We
would suggest to the authors that they reanalyse
pneumonia deaths and prescribing rates for LRTI in
these age groups and exclude bronchopneumonia
(ICD 9 code 485).
The statistical analysis considers only one time
variable and should in addition to cyclical changes
take account of secular changes and also should
adjust for time-varying factors such as new
initiatives. Data from the USA suggest that pneu-
monia mortality is increasing as part of a long-term
trend which began before reductions in antibiotic
prescribing began.4 Interestingly, Figure 2 in the
Price paper also suggests that the trend for a rise in
pneumonia mortality had begun by 1995/1996
before changes in antibiotic prescribing occurred
in 1997/1998. Additional data from before 1993/
1994 would have been helpful, but any attempt to
correct for death certificate coding changes would
be likely to be inaccurate. The authors chose to use
a constant 12-week period for all years. This will
over- and underestimate if the winter mortality
peaks did not fit neatly into this period each year.
The use of an arbitrary constant of 85% to produce
winter excess deaths means that in high summer
mortality years, the absolute number of excess
deaths could be lower in the winter than in a year
with a very low summer mortality. It is difficult to
know how standardization for influenza has been
applied in a meaningful way. Standardization needs
to be based on the age-specific incidence of illness
since influenza epidemics are highly variable in
their impact. Furthermore, incidence rates of
influenza-like illness reported in the WRS are
always considerably less than the rates of acute
bronchitis regardless of age. Acute bronchitis in the
elderly is highly consistent in the first few weeks of
the year and consistently related to mortality peaks
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(all cause mortality) though January is not con-
sistently the coldest month. There are considerable
limitations when examining individual cause mor-
tality in the oldest age groups in isolation from all
cause mortality.
The authors have been somewhat selective in
their use of references in the discussion. They cite
three publications in support of delay in antibiotic
prescribing being of prognostic importance in
pneumonia. One of these was a review paper5 and
the other two were studies of hospitalized patients,
not those managed by GPs in the community.6,7
They rightly report that antibiotics have been
shown to have a modest beneficial effect in
controlled trials in acute bronchitis and go on to
say that they are unlikely to cause harm in most
LRTI patients. However, the most up to date version
of their reference uses the term ‘The magnitude of
this benefit, however, is similar to that of the
detriment from potential adverse effects’ which
gives a slightly different emphasis.8 Benefit in the
individual must, in addition be balanced against
harm to the population, as is recognized to have
occurred as a result of the development of
antibiotic resistance in common bacterial patho-
gens due to inappropriate use of antibiotics in the
community.
Data from other studies are at variance with
those of Price et al. A study of the relationship
between GP-diagnosed respiratory infections and
antibiotic prescriptions using Prescription Pricing
Authority all age and all cashed prescription data
has shown that both have been falling since 1993.9
Further analysis of this dataset shows the ratio of
prescriptions for antibiotics (regardless of reason)
to persons presenting with LRTI actually increased
slightly over the period. This analysis took no
account of antibiotic prescribing for skin and
urinary tract infections, the incidence of which
had not changed over the same period. Never-
theless, since antibiotic prescribing is dominated by
respiratory infections the data do not suggest that
doctors are prescribing less antibiotics for the
patients who consulted.
Furthermore, there is strong evidence from a
prospective study that decreasing antibiotic use for
LRTI in adults does not result in increased office
visits for pneumonia, never mind increased mor-
tality.10 This intervention was associated with a
reduction in antibiotic use from 74% to 48%. There
were 542 patients in the intervention phase so that
140 (26%) fewer patients received antibiotics.
According to the analysis by Price et al. this should
have resulted in one additional death from CAP. In
fact, 0.7% of the intervention group had a return
office visit for pneumonia, which was not signifi-
cantly different from return visits for pneumonia in
the control cohort (1.5%).
It is our opinion that the methods used in this
publication do not support the conclusions reached.
Whilst the authors have observed that deaths
registered due to pneumonia have increased in
recent winters they have not demonstrated that
this is anything to do with prescribing for LRTI.
Despite the care used by the authors to stress the
association between results, there remains a
suggestion of a causative link. Thus, these conclu-
sions may be open to misinterpretation by the
uninformed reader. As the authors state, recent
initiatives have been directed at evidence-based
antibiotic prescribing to reduce inappropriate pre-
scribing and thus reduce the pressure that drives
the development of antimicrobial resistance. We
would be concerned if this had led to antibiotics
not being prescribed to those for whom such
prescription is appropriate and would welcome
good evidence that this was or was not occurring.
We do not consider that this paper is consistent
with this, but accept and support the need for more
robust research in this area.
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